// App-Quantinova.ai

5317 : A high throughput screen of the novel immuno-oncology target HPK1 identifies a range of chemical starting points for the development of potent and selective inhibitors

Researchers

Presenter

  • Denise Swift

Principal Investigators

  • Samantha Hitchin

  • Chris Tomlinson

  • Anindita Sengupta

  • Callum Taylor

  • Alec O'Keeffe

  • Grace Boden

  • John Unitt

  • Stuart Thomson

  • Allan M. Jordan

Medical Centers

  • Sygnature Discovery, Nottingham, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Programmed cell death protein 1

  • Cytotoxic T-lymphocyte-associated protein 4

  • L-serine

  • T-cell function

  • T-cell receptor

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved